BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27910903)

  • 1. Prostate Cancer Patients-Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics.
    Fernández-Peralbo MA; Gómez-Gómez E; Calderón-Santiago M; Carrasco-Valiente J; Ruiz-García J; Requena-Tapia MJ; Luque de Castro MD; Priego-Capote F
    Sci Rep; 2016 Dec; 6():38243. PubMed ID: 27910903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.
    Johnson H; Guo J; Zhang X; Zhang H; Simoulis A; Wu AHB; Xia T; Li F; Tan W; Johnson A; Dizeyi N; Abrahamsson PA; Kenner L; Feng X; Zou C; Xiao K; Persson JL; Chen L
    BMC Med; 2020 Dec; 18(1):376. PubMed ID: 33256740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
    Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen and other serum and urine markers in prostate cancer.
    Stephan C; Ralla B; Jung K
    Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
    Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer marker panel with single cell sensitivity in urine.
    Nickens KP; Ali A; Scoggin T; Tan SH; Ravindranath L; McLeod DG; Dobi A; Tacha D; Sesterhenn IA; Srivastava S; Petrovics G
    Prostate; 2015 Jun; 75(9):969-75. PubMed ID: 25808739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study.
    Struck-Lewicka W; Kordalewska M; Bujak R; Yumba Mpanga A; Markuszewski M; Jacyna J; Matuszewski M; Kaliszan R; Markuszewski MJ
    J Pharm Biomed Anal; 2015; 111():351-61. PubMed ID: 25684700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Urinary Volatile Organic Compounds (VOCs) for the Diagnosis of Prostate Cancer.
    Gao Q; Su X; Annabi MH; Schreiter BR; Prince T; Ackerman A; Morgas S; Mata V; Williams H; Lee WY
    Clin Genitourin Cancer; 2019 Jun; 17(3):183-190. PubMed ID: 30853355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection.
    Payne SR; Serth J; Schostak M; Kamradt J; Strauss A; Thelen P; Model F; Day JK; Liebenberg V; Morotti A; Yamamura S; Lograsso J; Sledziewski A; Semjonow A
    Prostate; 2009 Sep; 69(12):1257-69. PubMed ID: 19459176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of patients with and without prostate cancer using urine
    Hasubek AL; Wang X; Zhang E; Kobus M; Chen J; Vandergrift LA; Kurreck A; Ehret F; Dinges S; Hohm A; Tilgner M; Buko A; Habbel P; Nowak J; Mercaldo ND; Gusev A; Feldman AS; Cheng LL
    Magn Reson Chem; 2023 Dec; 61(12):740-747. PubMed ID: 37654196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.
    Rigau M; Ortega I; Mir MC; Ballesteros C; Garcia M; Llauradó M; Colás E; Pedrola N; Montes M; Sequeiros T; Ertekin T; Majem B; Planas J; Ruiz A; Abal M; Sánchez A; Morote J; Reventós J; Doll A
    Prostate; 2011 Dec; 71(16):1736-45. PubMed ID: 21520154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers.
    Mengual L; Lozano JJ; Ingelmo-Torres M; Izquierdo L; Musquera M; Ribal MJ; Alcaraz A
    BMC Cancer; 2016 Feb; 16():76. PubMed ID: 26856686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of novel urine and blood based prostate cancer biomarkers: a review.
    Dijkstra S; Mulders PF; Schalken JA
    Clin Biochem; 2014 Jul; 47(10-11):889-96. PubMed ID: 24177197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond PSA: The Role of Prostate Health Index (phi).
    Ferro M; De Cobelli O; Lucarelli G; Porreca A; Busetto GM; Cantiello F; Damiano R; Autorino R; Musi G; Vartolomei MD; Muto M; Terracciano D
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32053990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer.
    Prior C; Guillen-Grima F; Robles JE; Rosell D; Fernandez-Montero JM; Agirre X; Catena R; Calvo A
    World J Urol; 2010 Dec; 28(6):681-6. PubMed ID: 20632177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrophotometric photodynamic diagnosis of prostate cancer cells excreted in voided urine using 5-aminolevulinic acid.
    Nakai Y; Miyake M; Anai S; Hori S; Tatsumi Y; Morizawa Y; Onisi S; Tanaka N; Fujimoto K
    Lasers Med Sci; 2018 Sep; 33(7):1557-1563. PubMed ID: 29725946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
    PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.
    Nakayama K; Inoue T; Sekiya S; Terada N; Miyazaki Y; Goto T; Kajihara S; Kawabata S; Iwamoto S; Ikawa K; Oosaga J; Tsuji H; Tanaka K; Ogawa O
    PLoS One; 2014; 9(9):e107234. PubMed ID: 25233230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved sensitivity and specificity for prostate cancer diagnosis based on the urine PCA3/PSA ratio acquired by sequence‑specific RNA capture.
    Zheng K; Dou Y; He L; Li H; Zhang Z; Chen Y; Ye A; Liu W; Kong L
    Oncol Rep; 2015 Nov; 34(5):2439-44. PubMed ID: 26351770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.